Positive Prognostic Overall Survival Impacts of Methylated <i>TGFB2</i> and <i>MGMT</i> in Adult Glioblastoma Patients.

The multivariate model showed a highly significant effect of age at diagnosis ( p < 0.001), age interactions with TGFB2 methylation ( p = 0.001), and age with sex ( p = 0.014) ( Figure 2 ).

also in 82,236 other papers

There was a significant trend of increasing mOS across all four subsets of GBM patients ( p = 0.019; TGFB2 lowMe / MGMT highMe predicted mOS of 21.1 months, patients with TGFB2 highMe / MGMT lowMe predicted mOS of 21.2 months) ( Figure 1 A).

also in 6,184 other papers

GBM patients (N = 73) in the TGFB1 highMe group predicted an OS time of 17.2 (95% CI: 12.2–23.1, death events = 42) months, which was longer than the remaining patients but did not reach statistical significance (N = 219; 13.6 (95% CI: 12.5–15, death events = 165) months; Log-rank Chi-Square = 3.804, p = 0.051) ( Figure S1E ).

also in 75,278 other papers

The increase in the mOS difference between patients with high levels of TGFB1 and MGMT methylation compared to those with low levels of TGFB1 and MGMT methylation was borderline significant (14.5 versus 36.9 months, respectively; Adj. p = 0.051) ( Figure 1 B).

also in 6,767 other papers

The patients with TGFB1 and MGMT methylation showed an increasing trend of mOS related to increasing methylation levels ( p = 0.051): the mOS for TGFB1 lowMe / MGMT lowMe group of patients was 14.5 months; the mOS for TGFB1 lowMe / MGMT highMe group of patients was 17.9 months; the mOS for TGFB1 highMe / MGMT lowMe group of patients was 18.6 months; and the mOS for TGFB1 highMe / MGMT highMe group of patients was 36.9 months.

also in 37,718 other papers